Glyburide, a NLRP3 Inhibitor, Decreases Inflammatory Response and Is a Candidate to Reduce Pathology in Leishmania Braziliensis Infection

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2019 Jun 29

PMID 31252034

Citations 28

Authors

Augusto M Carvalho

Fernanda O Novais

Camilla S Paixao

Camila I de Oliveira

Paulo Roberto Lima Machado

Lucas P Carvalho

Phillip Scott

Edgar M Carvalho

Affiliations

Soon will be listed here.

Citing Articles

Cellular senescence-associated gene IFI16 promotes HMOX1-dependent evasion of ferroptosis and radioresistance in glioblastoma.

Zhou Y, Zeng L, Cai L, Zheng W, Liu X, Xiao Y Nat Commun. 2025; 16(1):1212.

PMID: 39890789 PMC: 11785807. DOI: 10.1038/s41467-025-56456-y.

Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for Infection.

Vazquez C, Encalada R, Jimenez-Galicia I, Gomez-Escobedo R, Rivera G, Nogueda-Torres B Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861083 PMC: 11768481. DOI: 10.3390/ph18010021.

The Skin Test Predicts Clinic-Immunologic and Therapeutic Outcomes in Cutaneous Leishmaniasis.

Guimaraes L, Zacarias E, Nolasco S, Filho A, Lago J, Machado P Pathogens. 2024; 13(11).

PMID: 39599571 PMC: 11597541. DOI: 10.3390/pathogens13111018.

Glyburide Suppresses Inflammation-Related Colorectal Tumorigenesis Through Inhibition of NLRP3 Inflammasome.

Maeda T, Shirakami Y, Taguchi D, Miwa T, Kubota M, Sakai H Int J Mol Sci. 2024; 25(21).

PMID: 39519191 PMC: 11546087. DOI: 10.3390/ijms252111640.

Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.

Lafleur A, Daffis S, Mowbray C, Arana B Vaccines (Basel). 2024; 12(10).

PMID: 39460345 PMC: 11511131. DOI: 10.3390/vaccines12101179.

References

Ponte-Sucre A, Campos Y, Vazquez J, Moll H, Mendoza-Leon A . Sensitivity of Leishmania spp. to glibenclamide and 4-aminopyridine: a tool for the study of drug resistance development. Mem Inst Oswaldo Cruz. 1998; 92(5):601-6. DOI: 10.1590/s0074-02761997000500007. View

Voronov E, Dotan S, Gayvoronsky L, White R, Cohen I, Krelin Y . IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol. 2010; 22(4):245-57. DOI: 10.1093/intimm/dxq006. View

Serrano-Martin X, Payares G, Mendoza-Leon A . Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother. 2006; 50(12):4214-6. PMC: 1693980. DOI: 10.1128/AAC.00617-06. View

Charmoy M, Hurrell B, Romano A, Lee S, Ribeiro-Gomes F, Riteau N . The Nlrp3 inflammasome, IL-1β, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice. Eur J Immunol. 2015; 46(4):897-911. PMC: 4828310. DOI: 10.1002/eji.201546015. View

Novais F, Carvalho A, Clark M, Carvalho L, Beiting D, Brodsky I . CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production. PLoS Pathog. 2017; 13(2):e1006196. PMC: 5325592. DOI: 10.1371/journal.ppat.1006196. View

Carneiro P, Conceicao J, Macedo M, Magalhaes V, Carvalho E, Bacellar O . The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis. PLoS One. 2016; 11(2):e0148084. PMC: 4739692. DOI: 10.1371/journal.pone.0148084. View

Carvalho L, Passos S, Schriefer A, Carvalho E . Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol. 2012; 3:301. PMC: 3463898. DOI: 10.3389/fimmu.2012.00301. View

Latz E, Xiao T, Stutz A . Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013; 13(6):397-411. PMC: 3807999. DOI: 10.1038/nri3452. View

Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira W, Passos S, Carvalho L . IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013; 9(3):e1003243. PMC: 3605236. DOI: 10.1371/journal.ppat.1003243. View

10.

Carvalho A, Magalhaes A, Carvalho L, Bacellar O, Scott P, Carvalho E . Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis. BMC Infect Dis. 2013; 13:529. PMC: 3870979. DOI: 10.1186/1471-2334-13-529. View

11.

Lima-Junior D, Costa D, Carregaro V, Cunha L, Silva A, Mineo T . Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania. Nat Med. 2013; 19(7):909-15. DOI: 10.1038/nm.3221. View

12.

Lamkanfi M, Mueller J, Vitari A, Misaghi S, Fedorova A, Deshayes K . Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009; 187(1):61-70. PMC: 2762099. DOI: 10.1083/jcb.200903124. View

13.

Santos D, Campos T, Saldanha M, Oliveira S, Nascimento M, Zamboni D . IL-1β Production by Intermediate Monocytes Is Associated with Immunopathology in Cutaneous Leishmaniasis. J Invest Dermatol. 2017; 138(5):1107-1115. PMC: 5912958. DOI: 10.1016/j.jid.2017.11.029. View

14.

Padron-Nieves M, Diaz E, Machuca C, Romero A, Ponte Sucre A . Glibenclamide modulates glucantime activity and disposition in Leishmania major. Exp Parasitol. 2009; 121(4):331-7. DOI: 10.1016/j.exppara.2008.12.008. View

15.

Fernandez-Figueroa E, Rangel-Escareno C, Espinosa-Mateos V, Carrillo-Sanchez K, Salaiza-Suazo N, Carrada-Figueroa G . Disease severity in patients infected with Leishmania mexicana relates to IL-1β. PLoS Negl Trop Dis. 2012; 6(5):e1533. PMC: 3358333. DOI: 10.1371/journal.pntd.0001533. View